HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART

Table 1

Prospective studies of combination chemotherapy for HIV-HL in the cART era.

Regimen	𝑁	Initial CD4 Count/μL,	Advanced stage	Extranodal disease	“B” symptoms	Response rate	Overall survival
EBV [32]	17	184	88%	77%	82%	82%	48% (36 m)
EBVP [33]	35	219	83%	84%	89%	91%	32% (36 m)
ABVD [34]	62	129	100%	N/R	89%	87%	76% (60 m)
Stanford V [35]	59	238	71%	47%	75%	89%	51% (36 m)
BEACOPP [36]	12	205	92%	42%	83%	100%	75% (36 m)
VEBEP [37]	71	248	70%	NR	NR	79%	69% (48 m)

EBV: epirubicin, bleomycin, vinblastine; EBVP: epirubicin, bleomycin, vinblastine, prednisone; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; VEBEP: vinorelbine, epirubicin, bleomycin, cyclophosphamide, prednisone; NR: not reported.